Curis entered into a Securities Purchase Agreement for the sale of 16,666,680 shares and accompanying warrants at an effective price of $0.51 per unit. The transaction is expected to generate approximately $8.5 million in gross proceeds, which will be used to fund research and development activities and working capital through initial Chronic Lymphocytic Leukemia data expected in December 2026. Existing Series A and C warrants were also amended to reduce their exercise price to $0.60 per share. Curis is a clinical-stage biotechnology company focused on developing treatments for cancer.
